Navigation Links
Paracetamol, one of most used analgesics, could slow down bone growth
Date:9/4/2007

In Medicine, paracetamol is used to soothe every kind of pain, from simple molar pain to pain produced by bone fractures. This medicine is one of the most used nowadays. However, research carried out at the Departamento de Enfermeria of the University of Granada showed that taking paracetamol slows down bone growth, as has been proved by in vitro studies.

Author of this work is Olga Garca Mart nez, and her analysis takes as a starting point several clinical processes in which accelerating bone growth is required. Certain anti-inflammatories such as paracetamol warns the researcher should be cautiously taken, specially in situations which require a rapid bone tissue regeneration, such as after placement of a prosthesis or dental implant. Other anti-inflammatories which have no effects on bone growth should be used instead. Results of her work can not be confirmed in humans but in vitro research shows without a question that paracetamol slows down bone regeneration.

Plasma rich in growth factors

Research of Garca Mart nez was carried out on osteoblasts (cells involved in bone regenerating processes), obtained via bone samples. Apart from the effects of paracetamol on bone cells in culture, the author also studied the effect of plasma rich in growth factors (obtained from patients' own blood and after a spinning process). Application of this plasma gel on bones accelerates their growth, without affecting other cell parameters such as the cell cycle or the antigenic profile.

It is therefore an easy technique which involves few risks for the patient, who will recover from bone defects more quickly.

Even though her work has been carried out on osteoblasts, Garca Mart nez states that it could also be used on other kinds of cells such as fibroblasts, and can therefore be used not only on bones but also on soft tissue, which would help to heal wounds and ulcers.


'/>"/>

Contact: Dr. Olga Garca Mart nez
ogm@ugr.es
34-653-686-734
Universidad de Granada
Source:Eurekalert

Related biology news :

1. Protein discovery could unlock the secret to better TB treatment
2. Tiny particles could solve billion-dollar problem
3. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
4. Spider Venom Could Yield Eco-Friendly Insecticides
5. First atlas of key brain genes could speed research on cancer, neurological diseases
6. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
7. A comprehensive response to HIV could prevent 10 million AIDS deaths in Africa by 2020
8. New Breast Cancer Test Could Save Lives
9. Discovery Could Lead To Novel Approaches In HIV Treatment
10. How the environment could be damaging mens reproductive health
11. Dead zone area in Gulf could be increasing, researchers say
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 2016 Ampronix facilitates superior patient care by providing unparalleled technology to leaders ... is the latest premium product recently added to the range of products distributed by ... ... ... LCD Medical Display- Ampronix News ...
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... 2016 , ... Mosio, a leader in clinical research patient ... and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the hurdle ... and strategies for clinical researchers. , “The landscape of how patients receive and ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
Breaking Biology Technology: